A Three-part, Randomized Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy, Young Subjects and Elderly Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs BC 007 (Primary)
- Indications Dilated cardiomyopathy
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Berlin Cures
- 17 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
- 17 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
- 21 Jun 2017 Study has changed from part two to part three,and dose of drug has also changed,hence patient number has also changed from 44 to74.